Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
41 hedge funds and large institutions have $7.34M invested in Statera Biopharma, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 4 closing their positions.
687% more call options, than puts
Call options by funds: $535K | Put options by funds: $68K
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
4% less capital invested
Capital invested by funds: $7.62M → $7.34M (-$280K)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$17.4K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$14.3K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$9.66K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.03K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$151K |
| 2 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$93.6K |
| 3 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$60K |
| 4 |
Goldman Sachs
New York
|
-$34.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$32.5K |
STAB Hedge Fund Activity: Q3 2013 in Review
41 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2013, worth a combined $7.34M — down 3.7% from $7.62M a quarter earlier.
Fund positioning in STAB was balanced in Q3 2013: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 11 trimmed.
The largest buyer was Wells Fargo, adding an estimated $17.4K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $151K.
- 41 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $7.34M of Statera Biopharma, Inc. Common Stock stock for Q3 2013, down 3.7% quarter-over-quarter.
- 4 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2013 and 4 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2013 was Wells Fargo, an estimated $17.4K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2013 was Jacobs Levy Equity Management, an estimated $151K sold.
Based on aggregated 13F filings for Q3 2013.